<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="527">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>16/09/2005</approvaldate>
  <actrnumber>ACTRN12605000434695</actrnumber>
  <trial_identification>
    <studytitle>The effect of Glycine Betaine on fasting and Post methionine load homocysteine concentrations in healthy volunteers.</studytitle>
    <scientifictitle>The effect of Glycine Betaine on fasting and Post methionine load homocysteine concentrations in healthy volunteers.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>N/A</healthcondition>
    <healthcondition>Healthy Volunteers</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2 />
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A 6-week intervention study investigating the effect of dietary manipulation versus dietary supplementation of glycine betaine on fasting and post-methionine load homocysteine concentrations.</interventions>
    <comparator />
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Homocysteine concentrations</outcome>
      <timepoint>At 0, 1, 2, 3, 4, 5, 6, 7, 8 and 24 hours post dose.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma glycine betaine, choline, methionine, and urine glycine betaine and choline concentrations.</outcome>
      <timepoint>At 0, 1, 2, 3, 4, 5, 6, 7, 8 and 24 hours post dose.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy volunteers with no previous history of vascular disease and no illness requiring medication, normal haemoglobin concentration.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>The presence of vitamin B12, vitamin B6 or folate deficiency, and/or 677C-&gt;T polymorphism in the methylene reductase gene.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed envelopes</concealment>
    <sequence>stratified, latin square design</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Bio-availability</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>11/08/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>8</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Canterbury health laboratories</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>National Heart Foundation</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>n/a</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Wendy Atkinson</name>
      <address>Specialist Biochemistry
Canterbury Health Laboratories
PO Box 151
Christchurch 8001</address>
      <phone>+64 3 3640122</phone>
      <fax />
      <email>wendy.atkinson@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Wendy Atkinson</name>
      <address>Specialist Biochemistry
Canterbury Health Laboratories
PO Box 151
Christchurch 8001</address>
      <phone>+64 3 3640122</phone>
      <fax />
      <email>wendy.atkinson@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>